Allergy

BENTONVILLE, Ark. — This weekend, Sam's Club is offering free allergy health screenings in select locations across the country.

Sam's Club said that its allergy tests, which are valued at $500, will screen participants for allergies to house and dust mites, cats, timothy grass, Bermuda grass, mountain cedar, short ragweed, alternaria (mold), milk, egg whites and wheat.

MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Tris Pharma for a drug to treat allergies in children ages 2 years and older, Tris said Wednesday.

Tris said that if approved, its carbinoxamine extended-release oral suspension would provide an alternative to currently available immediate-release formulations.

PLYMOUTH MEETING, Pa. — Pollen.com and Weather Trends International last month teamed together on a new forecast tool for allergy sufferers: a 28-day weather forecast by zip code to help people with allergies better plan when pollen levels are likely to be high in their area.

PARIS — Allegra is less than a week away from reaching shelves on March 4, and with the latest allergy switch will come a significant number of Rx allergy sufferers this summer.


JERUSALEM — An investigational drug made by Teva Pharmaceutical Industries for treating allergies is safe and effective, according to results of a late-stage clinical trial announced Wednesday.

Teva said the phase-3 trial of the nasally inhaled drug Qnaze (beclomethasone dipropionate) showed that it significantly relieved symptoms of seasonal and perennial allergic rhinitis compared with placebo while demonstrating a similar safety profile.

BASKING RIDGE, N.J. — Mylan subsidiary Dey Pharma has launched a mobile application for patients at risk of severe allergic reactions, which is tied to its EpiPen product.

The MyEpiPen app is available for the Apple iPhone, iPod Touch and iPad, and allows individuals, parents, guardians and others to create and share profiles of severe allergies with friends, family, teachers, school nurses, babysitters and others. Other features include an instructional video, user guide and others.

JERUSALEM — An investigative treatment for allergies made by Teva Pharmaceutical Industries appears to work, according to results of a late-stage clinical trial released Monday.

Teva said phase-3 data from a study of Qnaze HFA (beclomethasone dipropionate), designed to be inhaled through the nose, was effective in treating patients with seasonal allergic rhinitis, while safety results were similar to those for placebo. Data from the study were presented at the annual meeting of the American College of Allergy, Asthma & Immunology in Phoenix.